ACB - Aurora Cannabis Inc.
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.5143 |
| Open | 0.5200 |
| Bid | 0.5260 x 800 |
| Ask | 0.5263 x 1000 |
| Day's Range | 0.5031 - 0.5349 |
| 52 Week Range | 0.4900 - 1.9400 |
| Volume | |
| Avg. Volume | 3,445,950 |
| Market Cap | 180.45M |
| Beta (5Y Monthly) | 3.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.9500 |
| Earnings Date | Jun 06, 2023 - Jun 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.88 |
Fair Value
Related Research
PR NewswireAurora Celebrates Summer with New Innovation Launching Across Canada
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, is launching a fresh lineup of innovative products, available to patients on Aurora Medical and consumers, at retailers across the country this summer. The company's ever-expanding portfolio includes new 1mg format, snackable edibles, premium resin vape carts with big, bold flavour, and a true-to-form signature hash. New flower products include Chemango Kush, an original strain from Occo, Aurora's estee
PR NewswireAurora and Ethypharm Reaffirm their Commitment to Promote Access to Medical Cannabis for French Patients
Aurora Europe GmbH, a subsidiary of Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), and Ethypharm are pleased to announce that they have once again been selected by the French General Directorate of Health (DGS) as exclusive suppliers of dried medical cannabis flower until the end of the French trial period. The trial has recently been extended until March 2024.
Insider Monkey11 Best Marijuana Stocks To Buy Now
In this article, we discuss 11 best marijuana stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Marijuana Stocks To Buy Now. Previously, we reported that in 2022, the cannabis industry had a mixed performance, with some new markets experiencing growth while sales declined in established […]
Motley FoolThe Most Likely Scenario for Aurora Cannabis Stock Doesn't Look Good
Aurora Cannabis (NASDAQ: ACB) has been struggling for years. The stock is trading down to well under $1 per share, and another reverse stock split is inevitable for the company. Aurora Cannabis' stock price fell 96% over the past three years.
Motley FoolBetter Buy: Aurora Cannabis vs. Trulieve Cannabis
One was once a favorite among cannabis investors, but the other could become the top cannabis contender.
Motley FoolThis Troubled Stock Might Go Up in Smoke
It's been roughly five years since Canada legalized cannabis, and it's been an unpleasant ride for investors in Aurora Cannabis (NASDAQ: ACB), one of Canada's leading growers and operators. The company became a penny stock after surging to over $120 per share in 2018. While some may hope for a tremendous comeback story, sometimes a business model just isn't good.
CNW GroupAurora Expands Medical Cannabis Portfolio in Germany: New flower varieties for patients with high THC needs
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and a leading manufacturer and supplier of dried flower for medical patients worldwide, today announced the expansion of its portfolio in Germany with the launch of two new cannabis flower products for patients. Pedanios 27/1 FRG CA and Pedanios 29/1 SRD CA are dried cannabis flower with high tetrahydrocannabinol (THC) content. With these new therapeutic options now avai
Motley FoolBetter Growth Stock: Aurora Cannabis vs. Tilray Brands
Marijuana stocks have fallen out of favor in the last two years. The Canadian producers Aurora Cannabis (NASDAQ: ACB) and Tilray Brands (NASDAQ: TLRY) are two of the most popular marijuana companies. Aurora Cannabis has been investors' favorite among pot stocks for a while.
PR NewswireAurora Cannabis Partners with Strainprint to Empower Patients on their Cannabis Journey
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced the launch of a new tracking program designed to support and empower cannabis patients on their wellness journey.
CNW GroupAurora Introduces Fresh Innovation for Spring
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced a fresh lineup of innovative products. Coming soon to patients at Aurora Medical and to consumers at retail stores across the country, the company's expanded portfolio includes newly developed cultivars, strain-specific gummies and aromatic vapes. Flower products include two original strains from Occo, Aurora's esteemed breeding program: Pink Diesel '71 and Moon Berry.
PR NewswireAurora Repurchases ~$22 Million Principal Amount of Convertible Notes, Saving $1.2 Million in Annualized Interest Payments and Leaving ~$79 Million (US$59) of Notes Outstanding; Balance Sheet Remains Among Strongest in Canadian Cannabis Industry
Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced that it has repurchased an aggregate of approximately $22.3 million (US$16.6 million) principal amount of its convertible senior notes ("Notes") in multiple transactions since the start of April 2023 at a total cash cost, including accrued interest, of $16.7 million (US$12.4 million) and $5.3 million (US$4.0 million), including accrued interest, satisfied
Motley FoolHow Aurora Cannabis, Curaleaf, and SNDL Stack Up on 420 Day 2023
April 20th has a special significance for the cannabis industry. Three of those companies have especially attracted investors' attention in recent years -- Aurora Cannabis (NASDAQ: ACB), Curaleaf Holdings (OTC: CURLF), and SNDL (NASDAQ: SNDL) (formerly known as Sundial Growers). Aurora Cannabis is the worst of the group, with its share price plunging more than 80%.
InvestorPlace3 Penny Stocks to Sell Now While You Still Can
Penny stocks are enticing as they offer prospects of multibagger returns. High degree of speculation across penny stocks is another reason that makes it attractive for investors. Big trading gains are a possibility at the blink of an eye. However, amidst the ocean of names, there are penny stocks to avoid as they can continue to trend lower. It’s important to mention that among penny stocks, there are non-speculative stories. These stocks have strong fundamental support, making them a wise inves
Motley Fool3 Former High-Flying Stocks Down 92% to 99% That Billionaire Investors Can't Stop Buying
Despite losing most of their value, these former Wall Street darlings have been popular buys among billionaire money managers.
CNW GroupAurora and MedReleaf Australia Launch IndiMed Tempo 26, Further Strengthening Product Offerings for Medical Cannabis Patients
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and MedReleaf Australia today announced the launch of IndiMed Tempo 26, a range of new higher THC dried cannabis products for qualified patients under the MedReleaf Concession Scheme (MCS). Tempo 26 will add to the portfolio of products available, giving doctors the ability to prescribe from a wider range of options for medical cannabis patients.
Motley FoolWhich Canadian Cannabis Company Will Be the Next Takeover Target?
The Canadian government's decision to license over 1,000 cannabis producers, along with its inability to rein in black market operators, has been an unmitigated disaster for the country's top legal cultivators. Despite billions of dollars being spent on state-of-the-art cultivation facilities, brick-and-mortar retail outlets, and virtual storefronts, Canada's largest cannabis companies have been losing money at an alarming rate due to a vast oversupply of product in the country. In turn, profit margins have cratered across the industry, spurring some notable cannabis companies like Aurora Cannabis (NASDAQ: ACB), SNDL, and Tilray Brands to diversify into non-cannabis businesses like alcohol and vegetables in an effort to become cash-flow-positive.
Motley FoolBetter Buy: Aurora Cannabis vs. Green Thumb Industries
Marijuana stocks have performed poorly over the last two years. Cannabis analytics firm BDSA estimates that global cannabis sales will reach $57 billion by 2026, a 13% annual growth forecast from $30 billion in 2021, with bulk of this growth expected to be driven by the Canadian and American markets. Investment opportunities seem lucrative, and investors with a higher risk appetite might stand to profit handsomely in the long run in this volatile industry.
Motley FoolWhy Aurora Cannabis Stock Is Slumping Today
Canadian marijuana company Aurora Cannabis (NASDAQ: ACB) is having another bad day. The pot seller's shares were down by a noteworthy 4.34% on moderate volume as of 2:05 p.m. ET on Monday. Since the start of the year, Aurora's stock has now shed 27.5% of its value, and the share price has fallen well below the Nasdaq's $1 bid requirement, triggering a noncompliance notice from the exchange last month.
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Aurora announced the repurchase of convertible senior notes worth approximately $47 million, saving the company $2.6 million in annualized interest payments. Jushi Holdings reported preliminary Q4 and record full year 2022 financial results. Curaleaf announced $20 million acquisition in Key Takeaways; Psychedelic Sector Awakn’s proprietary treatment protocol for alcohol use disorder […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared fi
CNW GroupAurora Repurchases ~$47 Million Principal Amount of Convertible Notes, Saving $2.6 Million in Annualized Interest Payments; Balance Sheet Remains Among Strongest in Canadian Cannabis Industry
Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced that it has repurchased an aggregate of approximately $46.6 million (US$34.3 million) principal amount of its convertible senior notes ("Notes") at a total cost, including accrued interest, of $45.6 million (US$33.6 million) in cash, saving $2.6 million in annualized interest payments. Following completion of this repurchase, Aurora will have approximatel
Motley FoolDon't Buy the Hype: Aurora Cannabis' Transformation Hasn't Worked
Restructuring and changes in strategy are moves that businesses often deploy when they're facing challenges and headwinds. While Aurora Cannabis (NASDAQ: ACB) has been slashing costs and changing its operations in recent years, the company isn't out of the woods by any stretch. Among the biggest moves that Aurora has made in recent years has been to shift its business more toward medical marijuana.
Motley Fool2 Reasons to Buy Aurora Cannabis and 1 Reason to Sell It
Aurora Cannabis (NASDAQ: ACB) is one of the few Canadian cannabis retailers that is still seeing revenue growth, despite price compression and illegal sales negatively impacting the industry. The company is still losing money, but it appears to be edging its way toward profitability. Aurora's path to success includes branching out to international markets while focusing more on medical marijuana sales at home.
InvestopediaTop Cannabis Stocks for April 2023
Top-performing cannabis stocks include TerrAscend, OgraniGram Holdings, and Verano Holdings, which lead the industry in revenue growth even as inflation and declining demand hurt U.S. sales.
CNW GroupAurora Provides Update on Nasdaq Listing
Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced receipt of a notification letter (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") dated March 24, 2023, advising that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) as the bid price of the Company's listed securities had closed at less than US$1.00 per share over the last 30 consecutive business days (the "Min
Motley FoolWhy Pot Stocks Are Glowing Green Today
With fears of economic turbulence receding, Aurora Cannabis, Canopy Growth, and Organigram rebounded from their Monday declines.